Cytrellis has raised $28.5m from investors including pharmaceutical developer Merz as it continues clinical trials on its handheld dermatological device for aging skin.
US-based dermatological device developer Cytrellis Biosystems raised $28.5m on Tuesday in a series B round featuring aesthetics and neurotoxin developer Merz Pharma’s corporate venturing program unit.
Merz Venture Initiative was joined in the round by venture capital firms Arch Venture Partners and Biomatics Capital, as well as investment management firm Partner Fund Management.
Cytrellis Biosystems is developing a handheld aesthetic dermatological device that combats sagging facial skin associated with aging by removing multiple minute skin parcels.
The technology has demonstrated a positive…
